Cargando…

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry

INTRODUCTION: Near-complete skin clearance has become a rapidly achievable treatment goal for patients with psoriasis receiving systemic biologic therapies. However, real-world evidence for durability of near-complete skin clearance and risk factors associated with loss of near-complete skin clearan...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLean, Robert R., Sima, Adam P., Beaty, Silky, Jones, Eric A., Eckmann, Thomas, Low, Robert, McClung, Laura, Spitzer, Rebecca L., Stark, Jeffrey, Armstrong, April
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613189/ https://www.ncbi.nlm.nih.gov/pubmed/37759099 http://dx.doi.org/10.1007/s13555-023-01028-5

Ejemplares similares

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Characteristics of Patients with Crohn’s Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry
por: Fan, Yanni, et al.
Publicado: (2022)

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry
por: Cross, Raymond K, et al.
Publicado: (2022)

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States
por: Hopson, Sari, et al.
Publicado: (2023)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2023)

Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry
por: Sebba, Anthony, et al.
Publicado: (2023)

Santa Evita /
por: Martínez, Tomás Eloy
Publicado: (1995)

Evita : imagenes de una pasion
Publicado: (1997)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation
por: Weatherhead, Sophie C, et al.
Publicado: (2011)

Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis
por: Sarma, Nilendu
Publicado: (2017)

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Singh, Sanminder, et al.
Publicado: (2018)

Recurrent spontaneous clearance of psoriasis during exacerbations of concomitant chronic spontaneous urticaria
por: Magen, Eli, et al.
Publicado: (2020)

Individualised computational modelling of immune mediated disease onset, flare and clearance in psoriasis
por: Shmarov, Fedor, et al.
Publicado: (2022)

Verrucous psoriasis: A rare variant of psoriasis masquerading as verrucous carcinoma
por: Garvie, Kristen, et al.
Publicado: (2019)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Psoriasis and Psycho-Dermatology
por: Moon, Hee-Sun, et al.
Publicado: (2013)

Psoriasis
por: Hernández Martínez, Ayuliet
Publicado: (1996)

Psoriasis
por: Lerner, Marguerite R.
Publicado: (1959)

Psoriasis
Publicado: (1906)

Psoriasis
Publicado: (1903)

Psoriasis
por: Parker, George
Publicado: (1896)

Psoriasis
por: Barker, Jonathan
Publicado: (1997)

Psoriasis
por: Wordin, N. E.
Publicado: (1879)

Psoriasis
Publicado: (1885)

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
por: Armstrong, April, et al.
Publicado: (2022)

Relation between the Peripherofacial Psoriasis and Scalp Psoriasis
por: Kim, Kyung Ho, et al.
Publicado: (2016)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gud3q3rbjshbsulkoqcr6ogm82